• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Theravance Biopharma, Mylan Submit NDA for Revefenacin americanpharmaceuticacreview
    November 14, 2017
    The NDA is supported by the companies' Phase 3 program for revefenacin, which consisted of two replicate pivotal Phase 3 efficacy studies and a 12-month, open-label, active comparator safety study.
  • AbbVie Submits NDA for Elagolix americanpharmaceuticacreview
    September 07, 2017
    AbbVie in cooperation with Neurocrine Biosciences has submitted a New Drug Application (NDA) to the U.S.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service